Clinical Trials Logo

Nasopharyngeal Cancer clinical trials

View clinical trials related to Nasopharyngeal Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06268600 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

This study aimed to reduce radiation-induced thyroid injury without compromising control of the cervical region by optimizing the delineation of the cervical lymph node drainage area.

NCT ID: NCT06019130 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

NPC-Nivo
Start date: January 10, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess whether the addition of the immune checkpoint inhibitor Nivolumab to induction chemotherapy will increase the percentage of patients with a complete response on MRI and PET after 3 cycles of induction therapy.

NCT ID: NCT05983432 Recruiting - Breast Cancer Clinical Trials

Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Start date: August 8, 2023
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

NCT ID: NCT05638269 Recruiting - Lung Cancer Clinical Trials

A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China

Start date: March 1, 2022
Phase:
Study type: Observational

The human gut microbiome has been associated with many health factors but variability between studies limits the exploration of effects between them. This study aims to systematically characterize the gut microbiota of various critical chronic diseases, compare the similarities and differences of the microbiome signatures linked to different regions and diseases, and further investigate their impacts on microbiota-based diagnostic models.

NCT ID: NCT05628922 Recruiting - Clinical trials for Nasopharyngeal Cancer

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Start date: July 2, 2022
Phase: Phase 2
Study type: Interventional

Nasopharyngeal carcinoma is biologically different from traditional head and neck squamous cell carcinoma. The mainstay treatment for locally advanced nasopharyngeal carcinoma is cisplatin-based concurrent chemoradiation. Recent phase III randomized control trials have demonstrated that induction chemotherapy plus concurrent chemoradiation further improved progression-free survival. However, not every patient has good response to induction chemotherapy. Evidence has accumulated that those with poor response to induction chemotherapy, or those with detectable Epstein-Barr Virus (EBV) DNA post induction chemotherapy, correlated with poorer progression-free survival. Huang CL et al. (Int J Radiat Oncol Bio Phys. 2019) reported that plasma EBV DNA load at completion of induction chemotherapy was an independent and earlier predictor for progression-free survival and overall survival in locally advanced nasopharyngeal carcinoma. Lv J et al. (Nat Commun. 2019) demonstrated that real-time monitoring of plasma EBV DNA response added prognostic information, and had the potential uitility for risk-adapted treatment intensification in nasopharyngeal carcinoma. Therefore, investigators selects those with poor plasma EBV DNA response during and after induction chemotherapy, and intensifies the treatment with combination of anti-PD-1 antibody, in order to improve progression-free survival in locally advanced nasopharyngeal carcinoma, according to response-adapted strategy.

NCT ID: NCT05587374 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Start date: August 1, 2023
Phase: Phase 3
Study type: Interventional

The trial aimed to compare cadonilimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in high-risk locoregionally-advanced nasopharyngeal carcinoma (LANPC).

NCT ID: NCT05581550 Recruiting - Clinical trials for Nasopharyngeal Cancer

Somatostatin Receptor Imaging in NPC, EBV Related Cancers

Start date: June 29, 2020
Phase: N/A
Study type: Interventional

The study aims to describe the avidity of somatostatin receptors in locally advanced, metastatic and locally recurrent nasopharyngeal cancer (NPC) and to determine the proportion of NPC patients with high somatostatin receptor density that may benefit from future somatostatin targeted therapeutic trial plans. The investigators also aim to determine the presence of somatostatin receptors in other EBV related cancers.

NCT ID: NCT05261750 Recruiting - Clinical trials for Nasopharyngeal Cancer

Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer

Start date: April 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and potential of dendritic cells therapy and secretomes therapy for advanced nasopharyngeal cancer.

NCT ID: NCT05239143 Recruiting - Breast Cancer Clinical Trials

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Start date: February 15, 2022
Phase: Phase 1
Study type: Interventional

A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.

NCT ID: NCT05070247 Recruiting - Breast Cancer Clinical Trials

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Start date: April 14, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors. The aims of the study are: - to assess the safety profile of TAK-500 when given alone and when given with pembrolizumab. - to assess the anti-tumor effects of TAK-500, when given alone and when given with pembrolizumab, in adults with locally advanced or metastatic solid tumors. Participants may receive TAK-500 for up to 1 year. Participants may continue with their treatment if they have continuing benefit and if this is approved by their study doctor. Participants who are receiving TAK-500 either alone or with pembrolizumab will continue with their treatment until their disease progresses or until they or their study doctor decide they should stop this treatment.